Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529351 | 0.85 | HTT (0.54) | HTTSMN1; SMN2ALDH1A1KDM4EATM | |
| SCHEMBL31105819 | 0.85 | HTT (0.54) | HTTSMN1; SMN2ALDH1A1KDM4EATM | |
| SCHEMBL29754608 | 0.84 | IKBKB (0.67) | HTTSMN1; SMN2ALDH1A1KDM4EATM | |
| SCHEMBL3144090 | 0.84 | KDM4E (0.55) | HTTSMN1; SMN2ALDH1A1KDM4EATM | |
| SCHEMBL31301 | 0.84 | IKBKB (0.67) | HTTSMN1; SMN2ALDH1A1KDM4EATM | |
| Hydrochloric Acid SCHEMBL30026 | 0.84 | HTT (0.52) | HTTSMN1; SMN2ALDH1A1KDM4EATM | |
| SCHEMBL9622109 | 0.81 | IKBKB (0.50) | HTTSMN1; SMN2ALDH1A1KDM4EATM | |
| SCHEMBL3705378 | 0.81 | CNR2 (0.51) | HTTSMN1; SMN2ALDH1A1KDM4EATM | |
| SCHEMBL5139948 | 0.81 | HTT (0.60) | HTTSMN1; SMN2ALDH1A1KDM4EATM | |
| SCHEMBL20098513 | 0.80 | KDM4E (0.57) | HTTSMN1; SMN2ALDH1A1KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2019-01-29 | — | — | US | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-9783501-B2 | Substituted quinolines as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783501-B2 | Substituted quinolines as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| EP-2951168-B1 | QUINOLINE AND QUINOXALINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2016055792-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | PULMOCIDE LIMITED (GB) | 2016-04-14 | — | — | WO | disclosed |
| EP-2951168-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-9139529-B2 | Substituted quinoxalines as sodium channel modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2014120815-A9 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-14 | — | — | US | disclosed |
| WO-2014120815-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-2609084-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8470852-B2 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| WO-2012025237-A9 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-02-14 | — | — | WO | disclosed |
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-08-30 | — | — | US | disclosed |
| WO-2012025237-A1 | SUBSTITUTED 2-AMINO-QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220627-A1 | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | HTT 1457/4885SMN1; SMN2 1809/4885ALDH1A1 3096/4885 |
| US-10189863-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | AZI2, HRH4, ZC3HAV1 | HTT 1486/4885SMN1; SMN2 347/4885ALDH1A1 1873/4885 |
| US-20150336945-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, SCN2A | HTT 1086/4885SMN1; SMN2 900/4885ALDH1A1 1485/4885 |
| US-20140228371-A1 | QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, SCN2A | HTT 1086/4885SMN1; SMN2 900/4885ALDH1A1 1485/4885 |
| US-20170355717-A1 | NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES | ZC3HAV1, DHX15, AZI2 | HTT 2083/4885SMN1; SMN2 560/4885ALDH1A1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.